Compare · BDX vs KMTS
BDX vs KMTS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $40.04B, about 34.0x KMTS ($1.18B).
- Over the past year, BDX is down 14.2% and KMTS is down 2.4% - KMTS leads by 11.8 points.
- BDX has been more active in the news (9 items in the past 4 weeks vs 1 for KMTS).
- BDX has more recent analyst coverage (25 ratings vs 7 for KMTS).
- Company
- Becton Dickinson and Company
- Kestra Medical Technologies Ltd.
- Price
- $145.35-1.22%
- $20.30-4.40%
- Market cap
- $40.04B
- $1.18B
- 1M return
- -2.52%
- -1.91%
- 1Y return
- -14.20%
- -2.43%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 9
- 1
- Recent ratings
- 25
- 7
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
- Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by Becton Dickinson and Company
- SEC Form 4 filed by Director Huffines Robert Luther
Latest KMTS
- Officer Webster Brian Daniel sold $314,329 worth of shares (15,000 units at $20.96) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 334,786 units (SEC Form 4)
- Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
- Kestra Showcases Accelerated Innovation at HRS 2026
- SEC Form 4 filed by Webster Brian Daniel
- Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
- Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.
- SEC Form S-3ASR filed by Kestra Medical Technologies Ltd.
- SEC Form 4 filed by Cohen Raymond W
- Kestra Medical Technologies Named Finalist for 2026 GeekWire "Deal of the Year"
- SEC Form 4 filed by Webster Brian Daniel